Rare Diseases Congress Market Analysis and Reports | UK Conference Series

Market Analysis - Rare Diseases Congress 2017

Importance & scope:

Rare diseases are rare and often debilitating or even life-threatening diseases or conditions with a prevalence of 0.65%-1%, the cause of rare diseases is mostly genetic in nature and sometimes it may be as a result of infections or degenerative causes.

 80% of rare diseases have identified genetic origins, 50% of rare diseases affect children, and 30% of patients with rare diseases die before the age of 5. A rare disease is defined as one that affects less than 5 in 10,000 of the general population in European Union and fewer than 200,000 people in the United States. Worldwide it is estimated that 350 million people suffer from rare diseases. The above data urges a need for enhanced efforts in the fields of fundamental, translational, epidemiological, health services research and the current focus of Research studies is on Orphan drugs for safe and effective treatment. This 2nd World Congress Rare Diseases and Orphan Drugs would help researchers, academicians and young research fellows from across the globe to address the problem and unlock the understanding on rare diseases and its emerging technologies.

Why London?

Rare diseases are a complex group of heterogeneous maladies and are known for their irregularity. Just around 25% of uncommon diseases identified have their molecular basis characterized. There a numerous difficulties extending from illness acknowledgment to conclusion and advancement of new medications .UK has one of the biggest bio groups which work in association in this area of research,. London, the capital city of England is situated on River Thames nearby the island of Great Britain and is a popular tourist destination. London is a leading global city in areas of arts, commerce, education, entertainment, finance, healthcare, research facilities, tourist destination, and best transportation. London denote a one of a kind spot in rare diseases scientific research which includes top universities, research centres etc., these centres will provide research specialists the support and facilities they need to produce results. It also includes infrastructure that supports the research, and aims to consolidate its role as one of the world's driving places for the treatment of children with rare diseases. London and the neighbouring states are continuously endeavouring to create awareness and improve the health of individuals suffering from rare diseases. The EU has started a consortium in 2011 named “The International Rare Diseases Research Consortium” with an objective to develop new therapies and find novel methods to diagnose the disease. The UK has one of the strongest and most productive life sciences sectors in the world and London is a location of choice for pioneering, collaborative research of this nature. 2nd World Congress on Rare Diseases and Orphan Drugs to be held at London would benefit participants from all around the globe and drive forward research in this area.

Major Universities associated with Rare Diseases research

Australian National University, Australia

Benha University, Egypt

Center for Clinical Pharmacology, Belgium

Center for Rare Neurological Diseases, USA

Charles Darwin University Casoria Australia

Columbia University Medical Center, United States

Columbia University, USA

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Duke University, USA

Emory University, USA

GMEC, The Global Medical Excellence Cluster

Guangzhou Medical University, China

Harvard University, United States

Harvard University, USA

Imperial College London, United Kingdom

Iqbal Chest Centre, Bangladesh

John Hopkins University, USA

Johns Hopkins University, United States

Karolinska University, Sweden

Kindai University, Japan

King Saud Bin Abdulaziz University, Saudi Arabia

King's College London, UK

Kumamoto University, Japan

Linnaeus University, Sweden

Macquarie University, Australia

Mayo Clinic College of Medicine, USA

McGill university   Montréal, Canada

McMaster University, Canada

Medi7 Bentleigh, Australia

Murdoch University   Murdoch, Australia

Newcastle University, Australia

Northwestern University, Qatar

Osaka University, Japan

Oxford University, UK

Philip Morris International R&D, Switzerland

Pompeu Fabra University, Spain

Queen Mary University, UK

Rare Genomics Institute, USA

Research Institute of Hospital del Mar, Spain

Samsung Medical Center, South Korea

St George’s University of London, UK

St. George Hospital, Australia

Stanford University, USA

Tasmanian Health Service, Australia

The Chest & Heart Association of Bangladesh, Bangladesh

The Fourth Hospital of Harbin Medical University, China

The Jikei University School of Medicine, Japan

Tufts university, United States

United Hospital, Bangladesh

University College London, UK

University Of British Columbia, Canada

University Of Buffalo, United States

University Of California Los Angeles, United States

University of California, USA

University of Cambridge, USA

University of Canberra Bruce, Australia

University of Celiac Disease Center, USA

University Of Chicago Medicine, USA

University Of Colorado, USA

University Of Groningen, Netherlands

University Of London Imperial College Of Science Technology And Medicine, UK

University of Maastricht, Netherlands

University Of Maryland Medical  Center, United States

University Of Maryland Medical Center, Australia

University Of Melbourne, Australia

University Of Minnesota, United States

University of Newcastle, Australia

University of Pennsylvania, USA

University of Pittsburgh Study

University Of Pittsburgh, USA

University of Queensland, Australia

University of Tasmania, Australia

University Of Toronto, Canada

University of Valencia, Spain

University of Washington, USA

University Of Washington, USA

University of Zurich, Switzerland

University-of-the-sunshine-coast, Australia

Weill Cornell Medical College, Qatar

Yale University School of Medicine, USA

Yonsei University, South Korea

                

 

Major Research Associations related to Rare Diseases and Orphan Drugs

Alzheimer's Disease Organizations

Ann & Robert H. Lurie Children’s Hospital

Birmingham children’s Hospital

Boston Children’s Hospital

Canadian Organization for Rare Diseases

Chicago Rare Disease Foundation

Children’s hospital of Pittsburgh

Comer Children’s Hospital – University of Chicago

Cystic Fibrosis Foundation

European Union Committee of Experts on Rare Diseases

EURORDIS Rare Diseases Europe

EveryLife Foundation for Rare Diseases

Global Genes Allies in Rare Diseases

Guardian Hands Foundation

Hospitals Associated with Rare Diseases Research

IRDR Intractable & Rare Diseases Research

Japan Patient Association

Multiple Myeloma Research Foundation

National Alliances for Rare Diseases

National Institute of Health (NIH)

National Organization for Rare Diseases

Organization for Rare Diseases India (ORDI)

Orphan Europe

 Philippine Society for Orphan Disorders

Rare Disease UK

Rare Diseases or Syndromes and Clinical Societies

Rare Diseases Patient Association Funding

Rare Diseases South Africa

 Rare Diseases Translational Research Collaboration

Rare Disorders Society Singapore

RARE Foundation Alliance

Royal Society of Medicine

Short Bowel Syndrome Foundation

Students4RareDiseases

 The Asia-Pacific Alliance of Rare Disease Organisations

The Boler-Parseghian Center for Rare & Neglected Diseases

The Boler-Parseghian Center for Rare & Neglected Diseases

The Children’s Hospital of Philadelphia

The Every Life Foundation for Rare Diseases

The Genetic and Rare Disorders Organization

The Greek Alliance for Rare Diseases

The Manton Center for Orphan Disease Research

U.S. Food and Drug Administration

UCLA Health

US hospital for Rare Disease Research

                     

 

Major Companies Associated with Rare Diseases Research

Abbott Laboratories, UK

Actavis, USA

Aegerion Pharmaceuticals, Japan

Almirall, Spain

Amgen, USA

Amicus Therapeutics, USA

Amphastar Pharmaceuticals, Inc

Araim Pharmaceuticals

Astellas Pharma US

AstraZeneca, Switzerland

AstraZeneca, UK

Baxter International Deerfield

Bayer HealthCare, Germany

Bayer, Germany

Beacon Pharmaceuticals, Bangladesh

Biotie Therapies Corp, Finland

Bioxyne Limited, Australia

Boehringer Ingelheim, Germany

Centrapharm Ltd, UK

Chiesi Pharmaceutical, Italy

Cohero Health, USA

Daiichi Sankyo, Japan

Dohmen Life Science

European Medicines Agency

Forest Laboratories, USA

Gecko Health, USA

Generics (UK) Ltd, UK

Genus Oncology Vernon Hills, USA

Genzyme, USA

Gilead sciences, USA

GlaxoSmithKline, UK

Glaxosmithkline, UK

Gsk, London

Kissei Pharmaceutical Co., Ltd, Japan

Lallemand Pharma, Switzerland

Marathon Pharmaceuticals

Merck & Co, USA

Millennium Pharmaceuticals

Napp Pharmaceuticals Ltd, UK

Novartis, Switzerland

NPS Pharmaceuticals

Octapharma, USA

Onyx Pharmaceuticals, USA

Otsuka Holdings Co., Ltd, Japan

Panmira Pharmaceuticals, LLC, USA

Pearl Therapeutics, Inc

Pfizer, USA

PharmaMar, USA

Prosensa, Netherlands

PT Boehringer Ingelheim, Indonesia

Queensland Respiratory Laboratory Pty. Ltd, Australia

Ranbaxy Laboratories Limited

Raptor Therapeutics

Roche, Switzerland

Sanofi, France

Sarepta Therapeutics, USA

Sigma-Tau Pharmaceuticals, Italy

Sunovion Pharmaceuticals, USA

Swedish Orphan Biovitrum AB, Sweden

Takeda, Japan

Vertex Pharmaceuticals, USA

ViroPharma

ViroPharma

ViroPharma, USA

Visionary Pharmaceuticals, Inc, USA

Yungjin Pharm Ind. Co., Ltd, South Korea

                              

 

Market Research

There are more than 6,000 perceived uncommon diseases and it has been assessed that a further 5 are depicted every week.75% of rare diseases influence children.30% of rare disease patients die before 5 years old and,whilst each affects less than 0.1% of the population, the quantity of patients influenced by rare diseases is around 27-36 million in the EU, 25-30 million in the US, and 350 million people are affected around the world, but the true burden of rare diseases is difficult to estimate hard to evaluate subsequent to epidemiological information for most uncommon infections are not accessible. Among the rare diseases recognized and contemplated by EURORIDS it is found that 28.1% autosomal recessive inheritance,26.5% autosomal dominant inheritance, some are sporadic and few are with no etiology.There will be a steady increase in the cumulative number of diseases for which an orphan drug is approved, averaging just over 5 new diseases per year over the next 10 years. The annual per patient cost of global orphan drugs was varies between €1,251 and €407,631, with the median cost being €32,242 per year. The share of the total pharmaceutical market represented by orphan drugs is anticipated to increase from 3.3% in 2010 to a range of 4.6% in 2016 after which it is expected to level off through 2020. The global sales for orphan drugs are estimated at $178 billion, growing by11.7% per year, over the five year period between 2015 and 2020, nearly double the yearly growth of the overall prescription drug market, There are more than 6000 rare diseases are occurring. On the whole, rare diseases may affect 30 million European Union citizens, affects less than 1 in 2000.

Life expectancy 

Among the couple of rare diseases studied it is found that 37.5% had ordinary lifespan - 25.7% possibly deadly during childbirth or before 5 years old - 36.8% lessened lifespan, depending on the seriousness, penetrance or type (child, juvenile or adult types) of the disease.

 

                               

   

                         

 

Funds for research

EU has declared 38 million euro financing for exploration towards orphan medicines and for the improvement of a central worldwide rare disease hub involving 70 institutions. The EU subsidizing encouraged the arrangement of multidisciplinary groups from colleges, research associations, SMEs, industry and patient associations from crosswise over Europe and beyond. National Institute for Health Research had released funds of £5 million for each annum for the Rare Diseases Translational Research Collaboration furthermore NIH funded 19 proceeding and new clinical examination consortia to fortify the progressing clinical exploration in rare diseases.

 

Conference Series LLC invites all the participants from all over the world to attend “2nd World Congress on Rare Diseases and Orphan Drugs” during June 29-30, 2017  at London, UK which includes prompt keynote presentations, Oral talks, Poster Presentations and Exhibitions and B2B Meetings.

Conference Series LLC organizes 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Rare Diseases Congress-2017 meeting provides a forum for researchers in the field to share advances in Rare Diseases and orphan drugs related topics ranging from basic scientific research to biomarkers and clinical development, and it also throw a light on thought provoking topics and recent research in the field of infectious diseases related issues related to Rare Diseases. Rare Diseases Conference 2017  is a trending conference which brings together efficient academic scientists, super specialists, young researchers, professors, and doctors making a perfect platform to gain experience, and evaluate emerging health care strategies across the globe to discuss about the Rare Diseases and Orphan Drugs. Rare Diseases 2017conference involve in organizing the International symposiums, B2B meetings, International workshops along with the keynote and plenary presentations to discuss the research scope in the field of Rare Diseases.